Download PDF
Dtsch Med Wochenschr 2004; 129(47): 2547-2552
DOI: 10.1055/s-2004-835300
Übersichten
Hämostaseologie
© Georg Thieme Verlag Stuttgart · New York

Das Antiphospholipid-Syndrom

Klinische Manifestation, Diagnostik und TherapieThe antiphospholipid syndromeManifestation, diagnosis and therapyW. Miesbach1 , I. Scharrer1
  • 1Hämostaseologie, Zentrum der Inneren Medizin, Medizinische Klinik III, Universitätsklinik Frankfurt/Main
Further Information

Publication History

eingereicht: 2.4.2004

akzeptiert: 8.7.2004

Publication Date:
15 November 2004 (online)

Also available at
    Permissions and Reprints

Summary

Antiphospholipid antibody syndrome (APS) is characterised by the presence of frequently recurring venous and/or arterial thrombosis, abortions and repeated evidence of lupus anticoagulants and/or anticardiolipin (aCL)-antibodies. The presence of lupus anticoagulants and/or high levels of aCL-antibodies in particular increases the risk of thrombosis. At present there are several models for the systemic and cell-damaging pathogenesis of phospholipid-antibodies. Where there are repeated occurrences of thrombo-embolic complications long-term anticoagulant treatment is indicated. For patients who have APS in pregnancy, the use of low-molecular heparin and acetylsalicylic acid (ASS) is recommended. According to recent research, a large number of antibodies can be found in APS patients, which are directed against phospholipids and plasmaproteins, but partly also against individual genetic polymorphism, which suggests focussing in future on the genetic basis of APS as well as on influencing „auto-immune thrombosis” by modulating the immune system.

Literatur

  • 1 Alarcón-Segovia D, Boffa M C, Branch W. et al . Prophylaxis of the antiphospholipid syndrome: a consensus report.  Lupus. 2003;  12 499-503
    Google Scholar
  • 2 Alarcón-Segovia D, Pérez-Vázquez M E, Villa A R, Drenkard C, Cabiedes J. Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus.  Semin Arthritis Rheum. 1992;  21 275-286
    Google Scholar
  • 3 Alliot C, Messouak D, Albert F. Correction of thrombocytopenia with aspirin in the primary antiphospholipid syndrome.  Am J Hematol. 2001;  68 215
    Google Scholar
  • 4 Al-Saeed A. et al . The development of antiphospholipid antibodies in haemophilia is linked to infection with hepatitis C.  Br J Haematol. 1994;  88 845-848
    Google Scholar
  • 5 al Sayegh F A, Ensworth S, Huang S, Stein H B, Klinkhoff A V. Hemorrhagic complications of long-term anticoagulant therapy in 7 patients with systemic lupus erythematosus and antiphospholipid syndrome.  J Rheumatol. 1997;  24 1716-1718
    Google Scholar
  • 6 The APASS writing Committee . Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke.  JAMA. 2004;  291 576-584
    Google Scholar
  • 7 Asherson R A, Cervera R, de Groot P G. et al . Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines.  Lupus. 2003;  12 530-534
    Google Scholar
  • 8 Asherson R A, Cervera R, Piette J C. et al . Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients.  Medicine. 1998;  77 195-207
    Google Scholar
  • 9 Asherson R A, Doherty D G, Vergani D, Khamashta M A, Hughes G R. Major histocompatibility complex assiociations with primary antiphospholipid syndrome.  Arthrits Rheum. 1992;  35 124-125
    Google Scholar
  • 10 Bentolila S, Fremeaux-Bacchi V, Weiss L, Blouin J, Kazatchkine M D, Piette J C. High frequency of C4 „null” alleles in primary antiphospholipid syndrome.  Ann Med Interne. 1996;  147 115-116
    Google Scholar
  • 11 Blank M, Faden D, Tincani A. et al . Immunization with anticardiolipin cofactor (beta-2-glycoprotein I) induces experimental antiphospholipid syndrome in naïve mice.  J Autoimmun. 1994;  7 441-455
    Google Scholar
  • 12 Brandt J T, Triplett D A, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH.  Thromb Haemost. 1995;  74 1185-1190
    Google Scholar
  • 13 Carreno L, Monteagudo I, Lopez L F. et al . Anticardiolipin antibodies in pediatric patients with human immunodeficiency virus.  J Rheumatol. 1994;  21 1344-1346
    Google Scholar
  • 14 Cervera R, Khamashta M A, Font J. et al . Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on systemic lupus erythematosus.  Medicine. 1999;  78 167-175
    Google Scholar
  • 15 Cervera R, Piette J C, Font J. et al . Antiphospholipid Syndrome - Clinical and immunological manifestations and patterns of disease expression in a cohort of 1,000 patients.  Arthritis Rheum. 2002;  46 1019-1027
    Google Scholar
  • 16 Chapman J, Rand J H, Brey R L. et al . Non-stroke neurological syndromes associated with antiphospholipid antibodies: evaluation of clinical and experimental studies.  Lupus. 2003;  12 514-517
    Google Scholar
  • 17 Cheng Y, Wong R, Soo Y. et al . Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone.  N Engl J Med. 2003;  349 831-836
    Google Scholar
  • 18 Crowther M A, Ginsberg J S, Julian J. et al . A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome.  N Engl J Med. 2003;  349 1133-1138
    Google Scholar
  • 19 Diz-Kucukkaya R, Hacihanefioglu A, Yenerel M. et al . Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: A prospective cohort study.  Blood. 2001;  98 1760-1764
    Google Scholar
  • 20 Erkan D, Asherson R A, Espinosa G. et al . Catastrophic antiphospholipid syndrome registry project group. Long term outcome of catastrophic antiphospholipid syndrome survivors.  Ann Rheum Dis. 2003;  62 530-533
    Google Scholar
  • 21 Erkan D, Merill J T, Yazici Y, Sammaritano L, Buyon J P, Lockshin M D. High thrombosis rate after fetal loss in antiphospholipid syndrome - effective prophylaxis with aspirin.  Arthritis Rheum. 2001;  44 1466-1467
    Google Scholar
  • 22 Fabris F, Steffan A. et al . Specific antiplatelet antibodies in patients with antiphospholipid antibodies and thrombocytopenia.  Eur J Haematol. 1994;  53 232-236
    Google Scholar
  • 23 Facer C A, Agiostratidou G. High levels of anti-phospholipid antibodies in uncomplicated and severe Plasmodium falciparum and in P.vivax malaria.  Clin Exp Immunolol. 1994;  95 304-309
    Google Scholar
  • 24 Ferrara D E, Liu X, Espinola R G. et al . Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model.  Arthr Rheum. 2003;  48 3272-3279
    Google Scholar
  • 25 Finazzi G, Brancaccio V, Moia M. et al . Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the italian registry.  Am J Med. 1996;  100 530-536
    Google Scholar
  • 26 Font J, Jiménez S, Cervera R. et al . Splenectomy for refractory Evan’s syndrome associated with antiphospholipid antibodies: report of two cases.  Ann Rheum Dis. 2000;  59 920-923
    Google Scholar
  • 27 Galli M, Barbui T. Prevalence of different anti-phospholipid antibodies in systemic lupus erythematosus and their relationship with the antiphospholipid syndrome.  Clin Chem. 2001;  47 985-987
    Google Scholar
  • 28 Galli M, Confurius P, Massau C. et al . Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor.  Lancet. 1990;  335 1544-1547
    Google Scholar
  • 29 Galli M, Daldossi M, Barbui T. Anti-glycoprotein Ib/IX and IIb/IIIa antibodies in patients with antiphospholipid antibodies.  Thromb Haemost. 1994;  71 571-575
    Google Scholar
  • 30 Galli M, Finazzi G, Bevers E M, Barbui T. Kaolin clotting time and dilute Russel’s viper venome time distinguish between prothrombin- and ß2-glycoprotein-I-dependent antiphospholipid antibodies.  Blood. 1995;  86 617-623
    Google Scholar
  • 31 Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factor for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature.  Blood. 2003;  101 1827-1832
    Google Scholar
  • 32 Gharavi A E, Harris E N, Asherson R A, Hughes G RV. Isotype distribution and phospholipid specifity in the antiphospholipid syndrome.  Ann Rheum Dis. 1987;  46 1-6
    Google Scholar
  • 33 Godeau B, Piette J C, Fromont P, Intrator L, Schaeffer A, Bierling P. Specific antiplatelet glycoprotein autoantibodies are associated with the thrombocytopenia or primary antiphospholipid syndrome.  Br J Haematol. 1997;  98 873-879
    Google Scholar
  • 34 Harris E N, Gharavi A E, Hedge U. et al . Anticardiolipin antibodies in autoimmune thrombocytopenic purpura.  Br J Haematology. 1985;  59 231-234
    Google Scholar
  • 35 Jung F, Miesbach W, Scharrer I. Cardiac and cerebral manifestations of antiphospholipid syndrome.  Z Kardiol. 2002;  91 650-658
    Google Scholar
  • 36 Kaburaki J, Kuwana M, Yamamoto M, Kawai S, Ikeda Y. Clinical significance of anti-annexin V antibodies in patients with systemic lupus erythematosus.  Am J Hematol. 1997;  54 209-213
    Google Scholar
  • 37 Karassa F B, Bijl M, Davies K A. et al . Role of Fc-gamma receptor IIA polymorphism in the antiphospholipid syndrome: an international meta-analysis.  Arthritis Rheum. 2003;  48 1930-1938
    Google Scholar
  • 38 Khamashta M A, Cuadrado M J, Mujic F, Taub N A, Hunt B J, Hughes G RV. The management of thrombosis in the antiphospholipid-antibody syndrome.  N Engl J Med. 1995;  332 993-997
    Google Scholar
  • 39 Kutteh W H. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone.  Am J Obstet Gynecol. 1996;  174 1584-1589
    Google Scholar
  • 40 Lechner K, Pabinger-Fasching I. Lupus antikoagulant and thrombosis: a study of 25 cases and review of the literature.  Hemostasis. 1985;  15 254-262
    Google Scholar
  • 41 Levine S R, Brey R L, Sawaya K L. et al . Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome.  Ann Neurol. 1995;  38 119-124
    Google Scholar
  • 42 Levine S R, Salowich-Palm L, Sawaya K L. et al . IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study.  Stroke. 1997;  28 1660-1665
    Google Scholar
  • 43 Matsuura H, Igarasha T, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease.  Lancet. 1990;  336 117-118
    Google Scholar
  • 44 Mc Neil H D, Simpson R J, Chesterman C N, Krilis S A. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta-2-glycoprotein I (apolipiprotein H).  Proc Natl Acad Sci USA. 1990;  87 4120-4124
    Google Scholar
  • 45 Merill J T. Rituximab in antiphospholipid syndrome.  Curr Rheumatol Rep. 2003;  5 381-382
    Google Scholar
  • 46 Meroni P L, Moia M, Derksen R HWM. et al . Venous thromboembolism in the antiphospholipid syndrome: management guidelines for secondary prophylaxis.  Lupus. 2003;  12 504-507
    Google Scholar
  • 47 Miesbach W, Scharrer I, Asherson R A. Recurrent life-threatening thromboembolism and catastrophic antiphospholipid syndrome in a patient despite sufficient oral anticoagulation.  Clin Rheum. 2004;  23 256-261
    Google Scholar
  • 48 Muir K W, Squire I B, Alwan W, Lees K R. Anticardiolipin antibodies in an unselected stroke population.  Lancet. 1994;  344 452-464
    Google Scholar
  • 49 Munoz-Rodríguez F J, Font J. et al . Clinical study and follow-up of 100 patients with the antiphospholipid syndrome.  Semin Arthritis Rheum. 1999;  29 182-190
    Google Scholar
  • 50 Ogasawara M, Aoki K, Matsuura E, Sasa H, Yagami Y. Anti beta 2 glycoprotein I antibodies and lupus anticoagulant in patients with recurrent pregnancy loss: prevalence and clinical significance.  Lupus. 1996;  5 587-592
    Google Scholar
  • 51 Pasquier E, Amiral J, de Saint Martin L, Mottiert D. A cross sectional study of antiphospholipid-protein antibodies in patients with venous thromboembolism.  Thromb Haemost. 2001;  86 538-542
    Google Scholar
  • 52 Pattison N S, Chamley L W, McKay E J, Liggins G C, Butler W S. Antiphospholipid antibodies in pregnancy: prevalence and clinical associations.  Br J Obstet Gynaecol. 1993;  100 909-913
    Google Scholar
  • 53 Pengo V, Biasiolo A, Brocco T, Tonett S, Ruffatti A. Autoantibodies to phospholipid -binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies.  Thromb Haemost. 1996;  75 721-724
    Google Scholar
  • 54 Petri M. Classification and epidemiology of the antiphospholipid syndrome. First edition Amsterdam: Elsevier In Asherson A, Cervera R, Piette JC, Shoenfeld Y, editors. The antiphospholipid syndrome II 2002: 11-20
    Google Scholar
  • 55 Petri M. Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort.  Lupus. 2000;  9 170-175
    Google Scholar
  • 56 Rand J H, Wu X X, Andree H AM. et al . Antiphospholipid antibodies accelerate plama coagulation by inhibiting annexin-V binding to phospholipids: a „Lupus procoagulant” phenomen.  Blood. 1998;  92 1652-1660
    Google Scholar
  • 57 Rosove M H, Brewer P MC. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients.  Ann Intern Med. 1992;  117 303-308
    Google Scholar
  • 58 Salonen J T, Yla-Herttuala S, Yamamoto R. et al . Autoantibody against oxidized LDL and progression of carotid atherosclerosis.  Lancet. 1992;  339 883-887
    Google Scholar
  • 59 Schmidt R, Auer-Grumbach P, Fazekas F, Offenbacher H, Kapeller P. Anticardiolipin antibodies in normal subjects: Neuropsychological correlates and MRI findings.  Stroke. 1995;  26 749-754
    Google Scholar
  • 60 Sebastiani G D, Galeazzi M, Tincani A. et al . HLA-DPB1 alleles association of anticardiolipin and anti-beta 2GPI antibodies in a large series of European patients with systemic lupus erythematosus.  Lupus. 2003;  12 560-563
    Google Scholar
  • 61 Selva-O’Callaghan A, Ordi-Ros J, Monegal-Ferran F, Martinez N, Cortes-Hernandez F, Vilardell-Tarres M. IgA anticardiolipin antibodies - relation with other antiphospholipid antibodies and clinical significance.  Thromb Haemost. 1998;  79 282-285
    Google Scholar
  • 62 Shah N M, Khamashta M A, Atsumni T, Hughes G R. Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients.  Lupus. 1998;  7 3-6
    Google Scholar
  • 63 Shi W, Krilis S A, Chong B H, Gordon S, Chesterman C N. Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population.  Aust N Z J Med. 1990;  20 231-236
    Google Scholar
  • 64 Stasi R, Stipa E, Masi M. et al . Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura.  Am J Med. 1995;  98 436-442
    Google Scholar
  • 65 Sugi T, Katsunuma J, Izumi S, McIntyre J A, Makino T. Prevalence and heterogenity of antiphosphatidylethanolamine antibodies in patients with recurrent early pregnancy losses.  Fertil Steril. 1999;  71 1060-1065
    Google Scholar
  • 66 Tincani A, Branch W, Levy R A. et al . Treatment of pregnant patients with antiphospholipid syndrome.  Lupus. 2003;  12 524-529
    Google Scholar
  • 67 Tsapanos V, Kanellopoulos N. et al . Anticardiolipin antibodies levels in healthy pregnant and non-pregnant woman.  Arch Gynecol Obstet. 2000;  263 111-115
    Google Scholar
  • 68 Wilson W A, Gharavi A E, Koike T. et al . International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop.  Arthritis Rheum. 1999;  42 1309-1311
    Google Scholar
  • 69 Wisbey H L, Klestov A C. Thrombocytopenia corrected by warfarin in antiphospholipid syndrome.  J Rheum. 1996;  23 769-771
    Google Scholar
  • 70 Ziporen L, Shoenfeld Y. et al . Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies.  J Clin Invest. 1997;  100 613-619
    Google Scholar

Dr. med. Wolfgang Miesbach

Hämostaseologie, Zentrum der Inneren Medizin, Medizinische Klinik III, Universitäts-Klinik Frankfurt/Main

Theodor-Stern-Kai 7

60590 Frankfurt

Phone: 069/63015051

Fax: 069/63016738

Email: miesbach@em.uni-frankfurt.de

      >